Inhibiting the p53–MDM2 interaction: an important target for cancer therapy

Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours

Donehower, L. A., Harvey, M., Slagle, B. L., McArthur, M. J., Montgomery, C. A., Butel, J. S., & Bradley, A. (1992) · Nature · doi:10.1038/356215a0 · Cited by 4,649 · see citing works

Mdm2 promotes the rapid degradation of p53

Haupt, Y., Maya, R., Kazaz, A., & Oren, M. (1997) · Nature · doi:10.1038/387296a0 · Cited by 4,506 · see citing works

Regulation of p53 stability by Mdm2

Kubbutat, M. H. G., Jones, S. N., & Vousden, K. H. (1997) · Nature · doi:10.1038/387299a0 · Cited by 3,312 · cited 1× · see citing works

Live or let die: the cell's response to p53

Vousden, K. H., & Lü, X. (2002) · Nature reviews. Cancer · doi:10.1038/nrc864 · Cited by 3,177 · see citing works

The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation

Momand, J., Zambetti, G. P., Olson, D. C., George, D., & Levine, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90644-r · Cited by 3,113 · see citing works

Principles of protein-protein interactions

Jones, S., & Thornton, J. M. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.1.13 · Cited by 2,684 · see citing works

Structure of the MDM2 Oncoprotein Bound to the p53 Tumor Suppressor Transactivation Domain

Kussie, P. H., Gorina, S., Marechal, V., Elenbaas, B., Moreau, J., Levine, A. J., & Pavletich, N. P. (1996) · Science · doi:10.1126/science.274.5289.948 · Cited by 2,206 · see citing works

p63, a p53 Homolog at 3q27–29, Encodes Multiple Products with Transactivating, Death-Inducing, and Dominant-Negative Activities

Yang, A., Kaghad, M., Wang, Y., Gillett, E. S., Fleming, M. D., Dötsch, V., Andrews, N. C., Caput, D., & McKeon, F. (1998) · Molecular Cell · doi:10.1016/s1097-2765(00)80275-0 · Cited by 2,086 · see citing works

Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53

Honda, R., Tanaka, H., & Yasuda, H. (1997) · FEBS Letters · doi:10.1016/s0014-5793(97)01480-4 · Cited by 1,951 · see citing works

The p53-mdm-2 autoregulatory feedback loop.

Wu, X., Bayle, J. H., Olson, D., & Levine, A. J. (1993) · Genes & Development · doi:10.1101/gad.7.7a.1126 · Cited by 1,801 · see citing works

Monoallelically Expressed Gene Related to p53 at 1p36, a Region Frequently Deleted in Neuroblastoma and Other Human Cancers

Kaghad, M., Bonnet, H., Yang, A., Créancier, L., Biscan, J.-C., Valent, A., Minty, A. J., Chalon, P., Lélias, J.-M., Dumont, X., et al. (1997) · Cell · doi:10.1016/s0092-8674(00)80540-1 · Cited by 1,630 · see citing works

Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53

Oliner, J. D., Pietenpol, J. A., Thiagalingam, S., Gyuris, J., Kinzler, K. W., & Vogelstein, B. (1993) · Nature · doi:10.1038/362857a0 · Cited by 1,447 · see citing works

Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53

de Oca Luna, R. M., Wagner, D. S., & Lozano, G. (1995) · Nature · doi:10.1038/378203a0 · Cited by 1,420 · see citing works

mdm2 expression is induced by wild type p53 activity.

Barak, Y., Juven, T., Haffner, R., & Oren, M. (1993) · The EMBO Journal · doi:10.1002/j.1460-2075.1993.tb05678.x · Cited by 1,290 · see citing works

DNA Damage-Induced Activation of p53 by the Checkpoint Kinase Chk2

Hirao, A., Kong, Y., Matsuoka, S., Wakeham, A. C., Ruland, J., Yoshida, H., Liu, D., Elledge, S. J., & Mak, T. W. (2000) · Science · doi:10.1126/science.287.5459.1824 · Cited by 1,288 · see citing works

Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53

Jones, S. N., Roe, A. E., Donehower, L. A., & Bradley, A. (1995) · Nature · doi:10.1038/378206a0 · Cited by 1,280 · see citing works

The MDM2 gene amplification database

Momand, J. (1998) · Nucleic Acids Research · doi:10.1093/nar/26.15.3453 · Cited by 982 · see citing works

p53 and Human Cancer: The First Ten Thousand Mutations

Hainaut, P. L., & Hollstein, M. C. (1999) · Advances in cancer research · doi:10.1016/s0065-230x(08)60785-x · Cited by 980 · see citing works

The human homologs of checkpoint kinases Chk1 and Cds1 (Chk2) phosphorylate p53 at multiple DNA damage-inducible sites.

Shieh, S.-Y., Ahn, J., Tamai, K., Taya, Y., & Prives, C. (2000) · Genes & Development · doi:10.1101/gad.14.3.289 · Cited by 972 · see citing works

Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis

Eischen, C. M., Weber, J. D., Roussel, M. F., Sherr, C. J., & Cleveland, J. L. (1999) · Genes & Development · doi:10.1101/gad.13.20.2658 · Cited by 819 · see citing works

Computational Alanine Scanning To Probe Protein−Protein Interactions: A Novel Approach To Evaluate Binding Free Energies

Massova, I., & Kollman, P. A. (1999) · Journal of the American Chemical Society · doi:10.1021/ja990935j · Cited by 778 · see citing works

Mapping of the p53 and mdm-2 Interaction Domains

Chen, J., Maréchal, V., & Levine, A. J. (1993) · Molecular and Cellular Biology · doi:10.1128/mcb.13.7.4107 · Cited by 689 · see citing works

Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein.Preprint

Lin, J., Chen, J., Elenbaas, B., & Levine, A. J. (1994) · Genes & Development · doi:10.1101/gad.8.10.1235 · Cited by 652 · see citing works

MDMX: a novel p53‐binding protein with some functional properties of MDM2.

Shvarts, A., Steegenga, W. T., Riteco, N., van Laar, T., Dekker, P., Bazuine, M., van Ham, R. C., van der Houven van Oordt, W., Hateboer, G., van der Eb, A. J., et al. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00919.x · Cited by 648 · see citing works

p19ARF links the tumour suppressor p53 to Ras

Palmero, I., Pantoja, C., & Serrano, M. (1998) · Nature · doi:10.1038/25870 · Cited by 617 · see citing works

Nucleo‐cytoplasmic shuttling of the hdm2 oncoprotein regulates the levels of the p53 protein via a pathway used by the human immunodeficiency virus rev protein

Roth, J., Dobbelstein, M., Freedman, D. A., Shenk, T., & Levine, A. J. (1998) · The EMBO Journal · doi:10.1093/emboj/17.2.554 · Cited by 610 · see citing works

Phosphorylation of Ser-20 mediates stabilization of human p53 in response to DNA damage.

Chehab, N. H., Malikzay, A., Stavridi, E. S., & Halazonetis, T. D. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.24.13777 · Cited by 583 · see citing works

The p53/p63/p73 family of transcription factors: overlapping and distinct functions

Levrero, M., Laurenzi, V. D., Costanzo, A., Sabatini, S., Gong, J., Wang, J. Y. J., & Melino, G. (2000) · Journal of Cell Science · doi:10.1242/jcs.113.10.1661 · Cited by 563 · see citing works

Regulation of the p53 Tumor Suppressor Protein

Oren, M. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.51.36031 · Cited by 561 · see citing works

p63 and p73: p53 mimics, menaces and more

Yang, A., & McKeon, F. (2000) · Nature Reviews Molecular Cell Biology · doi:10.1038/35043127 · Cited by 504 · see citing works

Genetic determinants of p53-induced apoptosis and growth arrest.Preprint

Polyák, K., Waldman, T. A., He, T., Kinzler, K. W., & Vogelstein, B. (1996) · Genes & Development · doi:10.1101/gad.10.15.1945 · Cited by 458 · see citing works

Design of a synthetic Mdm2-binding mini protein that activates the p53 response in vivo

Böttger, A., Böttger, V., Sparks, A., Liu, W.-L., Howard, S. F., & Lane, D. P. (1997) · Current Biology · doi:10.1016/s0960-9822(06)00374-5 · Cited by 363 · see citing works

Nucleocytoplasmic shuttling of oncoprotein Hdm2 is required for Hdm2-mediated degradation of p53

Tao, W., & Levine, A. J. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.6.3077 · Cited by 355 · see citing works

mdm-2 Inhibits the G1 Arrest and Apoptosis Functions of the p53 Tumor Suppressor Protein

Chen, J., Wu, X., Lin, J., & Levine, A. J. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.5.2445 · Cited by 350 · see citing works

Molecular Mechanism of the Interaction between MDM2 and p53

Schön, O., Friedler, A., Bycroft, M., Freund, S. M. V., & Fersht, A. R. (2002) · Journal of Molecular Biology · doi:10.1016/s0022-2836(02)00852-5 · Cited by 349 · see citing works

MDM2 suppresses p73 function without promoting p73 degradation

Zeng, X., Chen, L., Jost, C. A., Maya, R., Keller, D., Wang, X., Kaelin, W. G., Oren, M., Chen, J., & Lu, H. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.5.3257 · Cited by 334 · see citing works

Tumor-suppressor p53: implications for tumor development and prognosis.

Kirsch, D. G., & Kastan, M. B. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.9.3158 · Cited by 301 · see citing works

Damage-mediated Phosphorylation of Human p53 Threonine 18 through a Cascade Mediated by a Casein 1-like Kinase

Sakaguchi, K., Saito, S., Higashimoto, Y., Roy, S., Anderson, C. W., & Appella, E. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.13.9278 · Cited by 293 · see citing works

The p53 and Mdm2 families in cancer

Michael, D. (2002) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(01)00264-7 · Cited by 288 · see citing works

Inhibition of Protein−Protein Association by Small Molecules: Approaches and Progress

Toogood, P. L. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm010468s · Cited by 281 · see citing works

Chalcone Derivatives Antagonize Interactions between the Human Oncoprotein MDM2 and p53

Stoll, R., Renner, C., Hansen, S., Palme, S., Klein, C., Belling, A., Żesławski, W., Kamionka, M., Rehm, T., Mühlhahn, P., et al. (2000) · Biochemistry · doi:10.1021/bi000930v · Cited by 275 · see citing works

Molecular characterization of the hdm2-p53 interaction 1 1Edited by J. Karn

Böttger, A., Böttger, V., Garcı́a-Echeverrı́a, C., Chêne, P., Hochkeppel, H. K., Sampson, W. R., Ang, K. H., Howard, S. F., Picksley, S. M., & Lane, D. P. (1997) · Journal of Molecular Biology · doi:10.1006/jmbi.1997.1078 · Cited by 251 · see citing works

Discovery of Potent Antagonists of the Interaction between Human Double Minute 2 and Tumor Suppressor p53

Garcı́a-Echeverrı́a, C., Chêne, P., Blommers, M. J. J., & Furet, P. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm990966p · Cited by 246 · see citing works

Immunochemical analysis of the interaction of p53 with MDM2;--fine mapping of the MDM2 binding site on p53 using synthetic peptides.

Picksley, S. M., Vojtĕsek, B., Sparks, A., & Lane, D. P. (1994) · PubMed · Cited by 238 · see citing works

What the papers say: The p53‐mdm2 autoregulatory feedback loop: A paradigm for the regulation of growth control by p53?

Picksley, S. M., & Lane, D. P. (1993) · BioEssays · doi:10.1002/bies.950151008 · Cited by 207 · see citing works

Alternative and aberrant splicing of MDM2 mRNA in human cancer

Bartel, F., Taubert, H. W., & Harris, L. C. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00091-0 · Cited by 196 · see citing works

Comparative study of the p53-mdm2 and p53-MDMX interfaces

Böttger, V., Böttger, A., Garcia-Echeverria, C., Ramos, Y. F., van der Eb, A. J., Jochemsen, A. G., & Lane, D. P. (1999) · Oncogene · doi:10.1038/sj.onc.1202281 · Cited by 189 · see citing works

Identification of novel mdm2 binding peptides by phage display.

Böttger, V., Böttger, A., Howard, S. F., Picksley, S. M., Chêne, P., Garcı́a-Echeverrı́a, C., Hochkeppel, H. K., & Lane, D. P. (1996) · PubMed · Cited by 182 · see citing works

Isolation and Structure Elucidation of Chlorofusin, a Novel p53-MDM2 Antagonist from a Fusarium sp.

Duncan, S. J., Grüschow, S., Williams, D. H., McNicholas, C., Purewal, R., Hájek, M., Gerlitz, M., Martin, S., Wrigley, S. K., & Moore, M. (2001) · Journal of the American Chemical Society · doi:10.1021/ja002940p · Cited by 171 · see citing works

P53: An ubiquitous target of anticancer drugs

Blagosklonny, M. V. (2001) · International Journal of Cancer · doi:10.1002/ijc.10158 · Cited by 146 · see citing works

A small synthetic peptide, which inhibits the p53-hdm2 interaction, stimulates the p53 pathway in tumour cell lines 1 1Edited by A. R. Fersht

Chêne, P., Fuchs, J. P., Bohn, J. A., Garcı́a-Echeverrı́a, C., Furet, P., & Fabbro, D. (2000) · Journal of Molecular Biology · doi:10.1006/jmbi.2000.3738 · Cited by 139 · see citing works

The Mdm2 Oncoprotein Interacts with the Cell Fate Regulator Numb

Juven‐Gershon, T., Shifman, O., Unger, T., Elkeles, A., Haupt, Y., & Oren, M. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.7.3974 · Cited by 136 · see citing works

The α-helical FXXΦΦ motif in p53: TAF interaction and discrimination by MDM2

Uesugi, M., & Verdine, G. L. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.26.14801 · Cited by 133 · see citing works

MDM2 and MDMX bind and stabilize the p53-related protein p73

Ongkeko, W. M., Wang, X. Q., Siu, W. Y., Lau, A. W. S., Yamashita, K., Harris, A. L., Cox, L. S., & Poon, R. Y. C. (1999) · Current Biology · doi:10.1016/s0960-9822(99)80367-4 · Cited by 132 · see citing works

HDM2 protein overexpression, but not gene amplification, is related to tumorigenesis of cutaneous melanoma.

Polsky, D., Bastian, B. C., Hazan, C., Melzer, K., Pack, J., Houghton, A., BUSAM, K. J., Cordon‐Cardo, C., & Osman, I. (2001) · PubMed · Cited by 120 · see citing works

p53 mediated death of cells overexpressing MDM2 by an inhibitor of MDM2 interaction with p53

Wasylyk, C., Salvi, R., Argentini, M., Dureuil, C., Delumeau, I., Abecassis, J., Debüssche, L., & Wasylyk, B. (1999) · Oncogene · doi:10.1038/sj.onc.1202528 · Cited by 112 · see citing works

Mdm2 overexpression and p14ARF inactivation are two mutually exclusive events in primary human lung tumors

Eymin, B., Gazzéri, S., Brambilla, C., & Brambilla, E. M. (2002) · Oncogene · doi:10.1038/sj.onc.1205359 · Cited by 104 · see citing works

Abnormal Expression of MDM2 in Prostate Carcinoma

Leite, K. R. M., de Franco, M. F., Srougi, M., Nesrallah, L., Nesrallah, A., Bevilacqua, R. G., Darini, E., Carvalho, C. M., Meirelles, M. I., Santana, I., et al. (2001) · Modern Pathology · doi:10.1038/modpathol.3880330 · Cited by 102 · see citing works

Efficient electrostatic solvation model for protein-fragment docking

Majeux, N., Scarsi, M., & Caflisch, A. (2000) · Proteins Structure Function and Bioinformatics · doi:10.1002/1097-0134(20010201)42:2 · Cited by 97 · see citing works

A Novel Cellular Protein (MTBP) Binds to MDM2 and Induces a G1 Arrest That Is Suppressed by MDM2

Boyd, M. T., Vlatković, N., & Haines, D. S. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m004252200 · Cited by 93 · see citing works

Peptides from the amino terminal mdm-2-binding domain of p53, designed from conformational analysis, are selectively cytotoxic to transformed cells

Kanovsky, M., Raffo, A. J., Drew, L., Rosal, R. V., Do, T., Friedman, F. K., Rubinstein, P., Visser, J. W. M., Robinson, R., Brandt‐Rauf, P. W., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.211280698 · Cited by 90 · see citing works

From p63 to p53 across p73

Strano, S., Rossi, M., Fontemaggi, G., Munarriz, E. R., Soddu, S., Sacchi, A., & Blandino, G. (2001) · FEBS Letters · doi:10.1016/s0014-5793(01)02119-6 · Cited by 87 · see citing works

Aib‐based peptide backbone as scaffolds for helical peptide mimics

Banerjee, R., Basu, G., Roy, S., & Chêne, P. (2002) · Journal of Peptide Research · doi:10.1034/j.1399-3011.2002.201005.x · Cited by 84 · see citing works

MDM2 oncogene as a target for cancer therapy: An antisense approach.

Wang, H., Zeng, X., Oliver, P. G., Le, L. P., Chen, J., Chen, L., Zhou, W., Agrawal, S., & Zhang, R. (1999) · International Journal of Oncology · doi:10.3892/ijo.15.4.653 · Cited by 82 · see citing works

The MDM2 C-terminal Region Binds to TAFII250 and Is Required for MDM2 Regulation of the Cyclin A Promoter

Léveillard, T., & Wasylyk, B. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.49.30651 · Cited by 81 · see citing works

The initial evaluation of non-peptidic small-molecule HDM2 inhibitors based on p53–HDM2 complex structure

Zhao, J., Wang, M., Chen, J., Luo, A., Wang, X., Wu, M., Yin, D., & Liu, Z. (2002) · Cancer Letters · doi:10.1016/s0304-3835(02)00084-8 · Cited by 80 · see citing works

Regulation of p63 Function by Mdm2 and MdmX

Kadakia, M., Slader, C., & Berberich, S. J. (2001) · DNA and Cell Biology · doi:10.1089/10445490152122433 · Cited by 73 · see citing works

Suppression of p53: a new approach to overcome side effects of antitumor therapy.

Komarova, E. A., & Gudkov, A. V. (2000) · PubMed · Cited by 69 · see citing works

p63 and p73: old members of a new family

Marín, M. C., & Kaelin, W. G. (2000) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(00)00010-x · Cited by 67 · see citing works

Thermodynamics of p53 Binding to hdm2(1–126): Effects of Phosphorylation and p53 Peptide Length

Lai, Z., Auger, K. R., Manubay, C. M., & Copeland, R. A. (2000) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.2000.1998 · Cited by 64 · see citing works

The proliferation of normal human fibroblasts is dependent upon negative regulation of p53 function by mdm2

Blaydes, J. P., & Wynford‐Thomas, D. (1998) · Oncogene · doi:10.1038/sj.onc.1201880 · Cited by 63 · see citing works

New Potent Sialyltransferase Inhibitors—Synthesis of Donor and of Transition-State Analogues of Sialyl Donor CMP-Neu5Ac

Amann, F., Schaub, C., Müller, B. H., & Schmidt, R. R. (1998) · Chemistry - A European Journal · doi:10.1002/(sici)1521-3765(19980615)4:6 · Cited by 58 · see citing works

Development of a Binding Assay for p53/HDM2 by Using Homogeneous Time-Resolved Fluorescence

Kane, S. A., Fleener, C., Zhang, Y., Davis, L. J., Musselman, A., & Huang, P. S. (2000) · Analytical Biochemistry · doi:10.1006/abio.1999.4413 · Cited by 47 · see citing works

Mdm-2 binding and TAFII31 recruitment is regulated by hydrogen bond disruption between the p53 residues Thr18 and Asp21

Jabbur, J. R., Tabor, A., Cheng, X., Wang, H., Uesugi, M., Lozano, G., & Zhang, W. (2002) · Oncogene · doi:10.1038/sj.onc.1205856 · Cited by 44 · see citing works

Study of the cytotoxic effect of a peptidic inhibitor of the p53–hdm2 interaction in tumor cells

Chêne, P., Fuchs, J. P., Carena, I., Furet, P., & Echeverrı́a, C. G. (2002) · FEBS Letters · doi:10.1016/s0014-5793(02)03362-8 · Cited by 39 · see citing works

Solution conformation of an essential region of the p53 transactivation domain

Botuyan, M. V., Momand, J. A., & Chen, Y. (1997) · Folding and Design · doi:10.1016/s1359-0278(97)00047-3 · Cited by 37 · see citing works

Targeting p53 in Cancer

Chêne, P. (2001) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1568011013354741 · Cited by 27 · see citing works

On the Interaction Between p53 and MDM2: Transfer NOE Study of a p53-Derived Peptide Ligated to MDM2

Blommers, M. J. J., Fendrich, G., Garcı́a-Echeverrı́a, C., & Chêne, P. (1997) · Journal of the American Chemical Society · doi:10.1021/ja9633171 · Cited by 24 · see citing works

The senescence-associated secretory phenotype: the dark side of tumor suppression

Coppé, J.-P., Desprez, P.-Y., Krtolica, A., & Campisi, J. (2010) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-121808-102144 · Cited by 5,206 · see citing works

In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2

Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661 · see citing works

Broadly applicable and accurate protein design by integrating structure prediction networks and diffusion generative models

Watson, J. L., Juergens, D., Bennett, N. R., Trippe, B. L., Yim, J., Eisenach, H. E., Ahern, W., Borst, A. J., Ragotte, R. J., Milles, L. F., et al. (2022) · doi:10.1101/2022.12.09.519842 · Cited by 2,369 · see citing works

De novo design of protein structure and function with RFdiffusion

Watson, J. L., Juergens, D., Bennett, N. R., Trippe, B. L., Yim, J., Eisenach, H. E., Ahern, W., Borst, A. J., Ragotte, R. J., Milles, L. F., et al. (2023) · Nature · doi:10.1038/s41586-023-06415-8 · Cited by 2,325 · see citing works

Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy

Tovar, C., Rosinski, J., Filipovic, Z., Higgins, B., Kolinsky, K., Hilton, H., Zhao, X., Vu, B. T., Qing, W., Packman, K., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0507493103 · Cited by 708 · see citing works

Structure-Based Design of Spiro-oxindoles as Potent, Specific Small-Molecule Inhibitors of the MDM2−p53 Interaction

Ding, K., Lu, Y., Nikolovska-Coleska, Z., Wang, G., Qiu, S., Shangary, S., Gao, W., Qin, D., Stuckey, J., Krajewski, K., et al. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm051122a · Cited by 702 · see citing works

Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition

Shangary, S., Qin, D., McEachern, D., Liu, M., Miller, R. S., Qiu, S., Nikolovska-Coleska, Z., Ding, K., Wang, G., Chen, J., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0708917105 · Cited by 660 · see citing works

Structure-based design of potent non-peptide MDM2 inhibitors

Ding, K., Lu, Y., Nikolovska-Coleska, Z., Qiu, S., Ding, Y., Gao, W., Stuckey, J., Krajewski, K., Roller, P. P., Tomita, Y., et al. (2005) · Journal of the American Chemical Society · doi:10.1021/ja051147z · Cited by 657 · see citing works

Senescent cells as a source of inflammatory factors for tumor progression

Davalos, A. R., Coppe, J.-P., Campisi, J., & Desprez, P.-Y. (2010) · Cancer and Metastasis Reviews · doi:10.1007/s10555-010-9220-9 · Cited by 636 · see citing works

MDM2 inhibitors for cancer therapy

Vassilev, L. T. (2007) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2006.11.002 · Cited by 532 · see citing works

Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials

Xie, X., Yu, T., Li, X., Zhang, N., Foster, L. J., Peng, C., Huang, W., & He, G. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01589-z · Cited by 396 · see citing works

Results of the Phase I trial of RG7112, a small-molecule MDM2 antagonist in leukemia

Andreeff, M., Kelly, K. R., Yee, K., Assouline, S., Strair, R., Popplewell, L., Bowen, D., Martinelli, G., Drummond, M. W., Vyas, P., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0481 · Cited by 352 · see citing works

Discovery of AMG 232, a Potent, Selective, and Orally Bioavailable MDM2–p53 Inhibitor in Clinical Development

Sun, D., Li, Z., Rew, Y., Gribble, M., Bartberger, M. D., Beck, H. P., Canon, J., Chen, A., Chen, X., Chow, D., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm401753e · Cited by 290 · see citing works

Cellular stress and nucleolar function

Mayer, C., & Grummt, I. (2005) · Cell Cycle · doi:10.4161/cc.4.8.1925 · Cited by 233 · see citing works

Combined MYC and P53 defects emerge at medulloblastoma relapse and define rapidly progressive, therapeutically targetable disease

Hill, R. M., Kuijper, S., Lindsey, J. C., Petrie, K., Schwalbe, E. C., Barker, K., Boult, J. K. R., Williamson, D., Ahmad, Z., Hallsworth, A., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2014.11.002 · Cited by 210 · see citing works

Levels of HdmX expression dictate the sensitivity of normal and transformed cells to Nutlin-3

Patton, J. T., Mayo, L. D., Singhi, A. D., Gudkov, A. V., Stark, G. R., & Jackson, M. W. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3832 · Cited by 189 · see citing works

Reactivation of mutant p53: molecular mechanisms and therapeutic potential

Selivanova, G., & Wiman, K. G. (2007) · Oncogene · doi:10.1038/sj.onc.1210295 · Cited by 186 · see citing works

Potent and orally active small-molecule inhibitors of the MDM2-p53 interaction

Yu, S., Qin, D., Shangary, S., Chen, J., Wang, G., Ding, K., McEachern, D., Qiu, S., Nikolovska-Coleska, Z., Miller, R., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm901400z · Cited by 180 · see citing works

Targeting Mdm2 and Mdmx in cancer therapy: better living through medicinal chemistry?

Wade, M., & Wahl, G. M. (2009) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-08-0423 · Cited by 170 · see citing works

The MDM2 inhibitor AMG 232 demonstrates robust antitumor efficacy and potentiates the activity of p53-inducing cytotoxic agents

Canon, J., Osgood, T., Olson, S. H., Saiki, A. Y., Robertson, R., Yu, D., Eksterowicz, J., Ye, Q., Jin, L., Chen, A., et al. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0710 · Cited by 152 · see citing works

Therapeutics targeting p53-MDM2 interaction to induce cancer cell death

Koo, N., Sharma, A. K., & Narayan, S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23095005 · Cited by 153 · see citing works

Discovery, Synthesis, and Biological Evaluation of Orally Active Pyrrolidone Derivatives as Novel Inhibitors of p53–MDM2 Protein–Protein Interaction

Zhuang, C., Miao, Z., Zhu, L., Dong, G., Guo, Z., Wang, S., Zhang, Y., Wu, Y., Yao, J., Sheng, C., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm300969t · Cited by 131 · see citing works

Structure–Activity Studies in a Family of β‐Hairpin Protein Epitope Mimetic Inhibitors of the p53–HDM2 Protein–Protein Interaction

Fasan, R., Dias, R. L. A., Moehle, K., Zerbe, O., Obrecht, D., Mittl, P. R. E., Grütter, M. G., & Robinson, J. A. (2006) · ChemBioChem · doi:10.1002/cbic.200500452 · Cited by 129 · see citing works

Discovery of a Small Molecule MDM2 Inhibitor (AMG 232) for Treating Cancer

Rew, Y., & Sun, D. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500627s · Cited by 125 · see citing works

A Small-Molecule Inhibitor of MDMX Activates p53 and Induces Apoptosis

Wang, H., Ma, X., Ren, S., Buolamwini, J. K., & Yan, C. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0581 · Cited by 117 · see citing works

Hepatic senescence, the good and the bad

Huda, N., Liu, G., Hong, H., Yan, S., Khambu, B., & Yin, X.-M. (2019) · World Journal of Gastroenterology · doi:10.3748/wjg.v25.i34.5069 · Cited by 100 · see citing works

Discovery of Mdm2-MdmX E3 Ligase Inhibitors Using a Cell-Based Ubiquitination Assay

Herman, A. G., Hayano, M., Poyurovsky, M. V., Shimada, K., Skouta, R., Prives, C., & Stockwell, B. R. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0104 · Cited by 100 · see citing works

Reactivation of p53 by a specific MDM2 antagonist (MI-43) leads to p21-mediated cell cycle arrest and selective cell death in colon cancer

Shangary, S., Ding, K., Qiu, S., Nikolovska-Coleska, Z., Bauer, J. A., Liu, M., Wang, G., Lu, Y., McEachern, D., Bernard, D., et al. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0140 · Cited by 91 · see citing works

Rational Design and Binding Mode Duality of MDM2–p53 Inhibitors

Gonzalez-Lopez de Turiso, F., Sun, D., Rew, Y., Bartberger, M. D., Beck, H. P., Canon, J., Chen, A., Chow, D., Correll, T. L., Huang, X., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400293z · Cited by 82 · see citing works

Phosphorylation of MDMX Mediated by Akt Leads to Stabilization and Induces 14-3-3 Binding

Lopez-Pajares, V., Kim, M. M., & Yuan, Z.-M. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m710030200 · Cited by 79 · see citing works

Small molecule modulators of protein-protein interactions: selected case studies

Aeluri, M., Chamakuri, S., Dasari, B., Guduru, S. K. R., Jimmidi, R., Jogula, S., & Arya, P. (2014) · Chemical Reviews · doi:10.1021/cr4004049 · Cited by 79 · see citing works

Plucking the high hanging fruit: A systematic approach for targeting protein–protein interactions

Raj, M., Bullock, B. N., & Arora, P. S. (2013) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2012.11.023 · Cited by 66 · see citing works

End-capped α-helices as modulators of protein function

Mahon, A. B., & Arora, P. S. (2012) · Drug Discovery Today: Technologies · doi:10.1016/j.ddtec.2011.07.008 · Cited by 44 · see citing works

Inhibition of the Akt/survivin pathway synergizes the antileukemia effect of nutlin-3 in acute lymphoblastic leukemia cells

Zhu, N., Gu, L., Li, F., & Zhou, M. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0179 · Cited by 42 · see citing works

PAHSAs reduce cellular senescence and protect pancreatic beta cells from metabolic stress through regulation of Mdm2/p53

Rubin de Celis, M. F., Garcia-Martin, R., Syed, I., Lee, J., Aguayo-Mazzucato, C., Bonner-Weir, S., & Kahn, B. B. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2206923119 · Cited by 39 · see citing works

A general synthesis of dirhodium metallopeptides as MDM2 ligands

Zaykov, A. N., & Ball, Z. T. (2011) · Chemical Communications · doi:10.1039/c1cc13169a · Cited by 27 · see citing works

Downregulation of cyclin D1 sensitizes cancer cells to MDM2 antagonist Nutlin-3

Yang, P., Chen, W., Li, X., Eilers, G., He, Q., Liu, L., Wu, Y., Wu, Y., Yu, W., Fletcher, J. A., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.8999 · Cited by 21 · see citing works

Inhibitors of MDM2 and MDMX: A Structural Perspective

Riedinger, C., & McDonnell, J. M. (2009) · Future Medicinal Chemistry · doi:10.4155/fmc.09.75 · Cited by 32 · see citing works

Sprouty4 is required for Mdm2 regulation of invasion, focal adhesion formation and metastasis in cells lacking p53Preprint

de Queiroz, R. M., Efe, G., Guzman, A., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.05.08.539890

Molecular mechanism of CCDC106 regulating the p53-Mdm2/MdmX signaling axis

Zhou, T., Ke, Z., Ma, Q., Xiang, J., Gao, M., Huang, Y., Cheng, X., & Su, Z. (2023) · Scientific Reports · doi:10.1038/s41598-023-47808-z · Cited by 4 · see citing works

Elevated MDM2 boosts the apoptotic activity of p53-MDM2 binding inhibitors by facilitating MDMX degradation

Xia, M., Knezevic, D., Tovar, C., Huang, B., Heimbrook, D. C., & Vassilev, L. T. (2008) · Cell Cycle · doi:10.4161/cc.7.11.5929 · Cited by 75 · see citing works

Molecular mechanism of CCDC106 regulating the p53-Mdm2/MdmX signal axisPreprint

Zhou, T., Cheng, X., Ke, Z., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-2619337/v1 · Cited by 1 · see citing works